Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

類似資料

• Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
  著者:: Rosenson, Robert S., 等
  出版事項: (2016)
• PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
  著者:: Blom, Dirk J, 等
  出版事項: (2016)
• PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
  著者:: Blom DJ, 等
  出版事項: (2016-05-01)
• Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia).
  著者:: Elisa Waldmann, 等
  出版事項: (2022-01-01)
• Long‐Term safety of pravastatin‐gemfibrozil therapy in mixed hyperlipidemia
  著者:: Iliadis, Elias A., 等
  出版事項: (2009)